Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy

Monica Galli, Manik Chatterjee, Mariella Grasso, Giorgina Specchia, Hila Magen, Hermann Einsele, Ivana Celeghini, Paola Barbieri, David Paoletti, Silvia Pace, Ralph D. Sanderson, Alessandro Rambaldi, and Arnon Nagler

Disclosures: MGa: consultancy, Leadiant Biosciences SA in liquidazione (previously Sigma Tau Research Switzerland SA); advisory role and travel support, Celgene, Janssen. HE: advisory role, Leadiant Biosciences SA in liquidazione; grants, Janssen, Celgene, Amgen, Novartis, Bristol-Myers Squibb. RDS: advisory role, preclinical research grant, Leadiant Biosciences SA in liquidazione; patent WO 2016/142814A1 licensed to Leadiant Biosciences SA in liquidazione. AR: honoraria, consultancy, Leadiant Biosciences SA in liquidazione; honoraria, consultancy, Amgen, Roche; honoraria, Novartis, Italfarmaco; travel support, Celgene. AN: honoraria, advisory role, Leadiant Biosciences SA in liquidazione; honoraria advisory role, symposium moderator, Takeda; honoraria advisory role, research grant, Amgen; research grants, Janssen, Celgene; honoraria advisory role, invited talks, Pfizer, Novartis, Sanofi. PB: employment, patent WO 2016/142814 A1 pending, Leadiant Biosciences SA in liquidazione. DP: employment, Leadiant Biosciences SA in liquidazione; SP: employment, Alfasigma SpA (previously Sigma Tau SpA). MC, MGr, GS, HM, IC: no conflicts of interest to disclose.

Contributions: Study conception and design: AN, AR, PB. Enrolment and treatment of patients, clinical data generation: MGa, MC, MGr, GS, HM, HE, IC, AR, AN. Data interpretation: AR, AN, HE, MGa, PB. PB drafted the manuscript and all authors contributed to revise the manuscript. All authors reviewed and approved the final version of the manuscript.